Pricing Log in Create free account
Friday 6 November 2026 Export ACH’s income statement to Excel — free account

Accendra Health, Inc.

ACH Healthcare Medical Distribution

Accendra Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 billion, up 3.06% from fiscal 2024.

Revenue
−10.1%
EPS
+89.7%
Free cash flow
−1,624.8%
Total debt
−13.1%

Quarter to June 2026, against a year earlier

0.27 0.01 −3.57%
Market cap
$23.0M
P/E
0.0×
Fwd P/E
−0.2×
Dividend yield
—
F-score
2/9
Altman Z
0.40
Beneish M
−2.92
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 9.47%

Capital & Financial Ratios $m

Size
Market Cap 22.95
Revenue ttm 2,647.25
Net income ttm (302.14)
Free cash flow ttm (210.90)
Net debt Q 1,710.41
Valuation
P/E 0.00
Forward P/E (0.17) (negative: loss-making)
Price / sales 0.01
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 0.41 (below 1: weak)
Debt / equity Q (3.12) (negative: negative equity)
Interest coverage Q (1.02)
Growth
Revenue growth Q −10.07% (below 0%: shrinking)
Operating income growth Q +11.48% (above 0%: growing)
EPS, this year −99.67% (below 0%: weak)
EPS, next year A +3,201.74% (at or above 15%: strong)
Revenue, next year A −9.81% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A −15.15% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.9×, against a ten-year median of 0.3×; over the ten years it ranged from 0.2× in 2019 to 1.1× in 2025.
P/S against its own 10 years 0.51%
10-year low 10-year high
EV/Sales against its own 10 years 90.98%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—
Growth, 2017–25
−100.0%/yr
  1. 1.03 ’17
  2. 0.86 ’18 −17
  3. 0.01 ’19 −99
  4. 0.01 ’20 +0
  5. 0.01 ’21 +0
  6. 0.12 ’22 +1090
  7. 0.10 ’23 −13
  8. 0.00 ’24 −100
  9. 0.00 ’25
paid change on the year, % Powerpack

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 243 28 282 8
Receivables 598 218 96 120
Inventory 1,111 68 74 73
Other 151 82 96 70
2,103 2,021 548 271
2023 2024 2025 Q'26
Payables 1,172 360 364 353
ST’ Debt 207 43 250 —
Other 397 295 264 272
1,892 1,852 947 666

Compound Annual Growth %

10y 5y 3y
Sales (11.87%) (20.10%) (34.78%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.13 Actual −0.19

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY24 0.40 0.42 Beat by 0.02
Q4 FY25 0.22 0.21 Miss by 0.01
Q1 FY26 −0.06 −0.04 Beat by 0.02
Q2 FY26 −0.13 −0.19 Miss by 0.06
Q3 FY26 −0.05 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.08) (1.16) — — —
’25 (0.32) (11.30) (1.94) (0.73) (14.31)
’24 (0.29) (0.42) (0.17) (3.84) (4.73)
’23 (0.32) (0.37) (0.08) 0.23 (0.54)
’22 0.52 0.37 0.16 (0.77) 0.29
’21 0.98 0.87 0.58 0.55 2.94
’20 (0.19) (0.91) 0.76 0.72 0.47
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 628 613 — — —
’25 674 682 697 709 2,762
’24 638 660 687 695 2,680
’23 2,523 2,563 2,592 2,656 2,553
’22 2,407 2,500 2,497 2,551 9,955
’21 2,327 2,489 2,502 2,467 9,785
’20 2,123 1,808 2,188 2,362 8,480
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (50) (26) — — —
’25 (35) 38 (173) 68 (102)
’24 (53) 116 27 71 161
’23 158 313 157 112 741
’22 80 90 69 87 325
’21 25 (13) 61 50 124
’20 93 57 118 71 339
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 4 (59) — — —
’25 (66) (3) (239) 84 (225)
’24 (53) 88 (16) 30 49
’23 124 282 125 103 634
’22 69 41 43 54 207
’21 19 (25) 48 33 74
’20 88 51 104 38 280
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 9,723 9,318 9,418 9,211 8,480 9,785 9,955 2,553 2,680 2,762 2,647 (13.1%) 2,491 2,564 2,684 (1.0%)
Gross margin, % 12.21 12.58 11.37 12.25 15.10 15.46 18.35 47.68 47.77 46.68 44.83 +34.5 pt
EBT 173 57 (427) (29) 110 277 11 15 (330) (102) (115) n/m
EBT margin, % 1.77 0.62 (4.53) (0.31) 1.30 2.83 0.11 0.60 (12.31) (3.69) (4.36) (5.5) pt
Net income 109 73 (437) (62) 30 222 22 (41) (363) (1,101) (302) n/m
Per share, $
Per share, $ Revenue 159.16 155.30 156.93 152.06 133.82 134.52 133.64 33.68 34.92 35.92 34.52 (15.2%)
Earnings 1.76 1.20 (7.28) (1.03) 0.47 3.05 0.30 (0.54) (4.73) (14.31) (3.91) n/m
Cash flow 3.07 0.95 1.93 2.74 5.35 1.71 4.36 9.77 2.10 (1.32) (2.35) n/m
Capex (0.41) (0.83) (1.07) (0.86) (0.93) (0.68) (1.59) (1.41) (1.47) (1.60) (0.40) +16.5%
Free cash flow 2.67 0.11 0.86 1.88 4.42 1.02 2.78 8.36 0.64 (2.93) (2.75) n/m
Book value 15.71 16.92 8.64 7.63 11.24 12.90 12.69 12.19 7.64 (5.99) (7.18) n/m
Shares, m 61 60 60 61 63 73 74 76 77 77 77 +2.6%
Valuation, ×
Valuation, × P/E 20.51 16.01 0.00 0.00 69.36 14.26 63.23 0.00 0.00 0.00 0.00 18.3
P/S 0.23 0.12 0.04 0.03 0.20 0.32 0.15 0.14 0.37 0.08 0.01 0.2
P/B 2.31 1.14 0.73 0.68 2.41 3.37 1.54 1.58 1.71 0.00 0.00 1.5
EV/Sales 0.29 0.23 0.23 0.19 0.31 0.42 0.39 0.32 1.05 0.72 0.87 0.4
EV/FCF 17.18 322.51 41.94 15.70 9.47 55.05 18.82 5.23 57.77 (8.81) (10.96) 53.5
Cash, $m
Cash, $m Operating cash flow 188 57 116 166 339 124 325 741 161 (102) (180) n/m
Capex (25) (50) (64) (52) (59) (50) (118) (107) (113) (123) (30) +19.5%
Free cash flow 163 7 52 114 280 74 207 634 49 (225) (211) n/m
Balance, $m
Balance, $m Working capital 927 872 1,067 991 790 978 729 211 169 (399) (395) n/m
Net debt 379 796 1,582 1,474 937 936 2,431 1,854 1,814 1,768 1,710 +18.7%
Shareholders’ equity 960 1,015 518 462 712 939 946 924 586 (461) (551) n/m
Returns, %
Returns, % ROA 3.92 2.35 (12.22) (1.68) 0.86 6.45 0.50 (0.79) (7.44) (30.97) (9.65) (34.9) pt
ROIC 9.32 3.08 (10.49) 2.36 7.74 12.29 2.64 3.00 (5.67) 1.31 1.58 (8.0) pt
ROE 11.03 7.26 (56.98) (12.72) 5.09 26.85 2.38 (4.42) (48.02) (1,755.61) 72.63 (1,766.6) pt
People
People Employees 7,900 8,600 17,900 15,400 18,800 17,300 22,500 22,200 23,200 6,500 — (2.1%)
Revenue/emp, $m 1.23 1.08 0.53 0.60 0.45 0.57 0.44 0.11 0.12 0.42 — (11.1%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Accendra Health, Inc. vs peers in Medical Distribution (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
HSIC Henry Schein, Inc. $9.4B 22.8× 21.3× +3.95% (above 0%: growing) +34.81% (above 0%: growing) −7.09% (below 0%: shrinking) 31.84% 5.56% Compare
AHG Akso Health Group Sponsored ADR $1.1B — (loss-making) — (loss-making) +263.89% (above 0%: growing) n/m −12,975.04% (below 0%: shrinking) 0.00% 0.00% Compare
FOCL FocalTherics $159.3M — (loss-making) — (loss-making) +38.85% (above 0%: growing) n/m +21.49% (above 0%: growing) 55.59% (60.83%) Compare
COSM Cosmos Health Inc. $29.2M — (loss-making) — (loss-making) +28.76% (above 0%: growing) n/m +9.39% (above 0%: growing) 7.96% (15.41%) Compare
ACH Accendra Health, Inc. $23.0M — (loss-making) — (loss-making) −10.07% (below 0%: shrinking) n/m −1,624.82% (below 0%: shrinking) 42.95% (5.73%)
YI 111, Inc. Sponsored ADR $15.5M — (loss-making) — (loss-making) −29.61% (below 0%: shrinking) n/m −185.70% (below 0%: shrinking) 5.33% (0.85%) Compare
MEDS DataMeds AI, Inc $5.5M — (loss-making) — −77.15% (below 0%: shrinking) n/m −41.85% (below 0%: shrinking) 10.24% (412.67%) Compare
HKPD Cellyan Biotechnology Co., Ltd $3.4M — — — — −90.45% (below 0%: shrinking) — — Compare
SNYRQ Synergy CHC Corp. $1.3M — (loss-making) 1.6× −32.77% (below 0%: shrinking) n/m −148.51% (below 0%: shrinking) 72.29% (10.32%) Compare
Median of peers $22.3M — — +3.95% — −66.15% 10.24% (10.32%)

All 12 Medical Distribution stocks →

Pay and ownership Proxy statement filed 29 October 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 11.16m (1.11m) 10.00
2024 10.74m 6.63m 48.00
2023 8.39m 2.43m 71.00
2022 6.25m (20.49m) 72.00
2021 7.68m 42.84m 161.00

Ownership

Directors and executive officers, together less than 1%
Coliseum Capital Management, LLC 17.02%
Bank of America Corporation 10.75%
BlackRock, Inc. 7.09%
Kevin M. Webb 5.57%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Accendra Health, Inc. (ACH) Latest News

6 Nov

Impact 4 · · GuruFocus.com

5 Nov

Impact 4 · · Business Wire

22 Oct

Impact 3 · · Business Wire

9 Oct

Impact 4 · · Business Wire

17 Sep

Impact 4 ·

17 Aug

Impact 3 · · InvestorsHub
Impact 3 ·

10 Aug

Impact 3 ·

23 Jun

Impact 3 · · Business Wire

10 Jun

Impact 3 · · MT Newswires
Impact 3 · · Business Wire

22 May

Impact 4 · · Business Wire

12 May

Impact 3 · · GuruFocus.com

11 May

Impact 4 · · The Motley Fool transcript
Impact 4 · · InvestorsHub
Impact 4 · · Business Wire

24 Feb

Impact 4 · · Insider MonkeyGuruFocus.comSimply Wall St.StockStoryInsider MonkeyInsider MonkeyMotley FoolSimply Wall St.

20 Feb

Impact 4 · · GuruFocus.com

19 Feb

Impact 3 · · Business Wire

8 Feb

Impact 3 · · Simply Wall St.

4 Feb

Impact 3 · · PR Newswire

8 Jan

Impact 4 · · Zacks

31 Dec

Impact 4 · · PR Newswire
Impact 4 · · Business Wire

18 Dec

Impact 3 · · Business WireMT NewswiresInsider MonkeyMT Newswires

9 Dec

Impact 4 · · 24/7 Wall St.

5 Dec

Impact 3 · · Zacks

11 Nov

Impact 3 · · Barchart

1 Nov

Impact 3 · · Simply Wall St.GuruFocus.comZacksSimply Wall St.MT Newswires

30 Oct

Impact 4 ·
stockrow.com/ACH · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com